Data Quality in Small QTc Studies. Marek Malik, London

Size: px
Start display at page:

Download "Data Quality in Small QTc Studies. Marek Malik, London"

Transcription

1 Data Quality in Small QTc Studies Marek Malik, London

2 Data Quality in Small QTc Studies DISCLAIMER Views and opinions presented are only my own

3 Data Quality in Small QTc Studies The E14 Guidance on conducting thorough QT studies needs revisiting. Different replacement and/or modification concepts have been proposed. Most expect the QT/QTc investigations to be moved into the very early clinical tests, such as the SAD and MAD FIM studies. This presentation is devoted to some aspects that should make the QT/QTc investigations as part of FIM studies practical and viable.

4 Data Quality in Small QTc Studies Electrocardiographic challenges of small clinical studies such as the first-in-man investigations Metrics of QTc data quality, power considerations of small studies Replacement and/or avoidance of standard positive control in small QTc studies and in conc-qtc analyses Approaches to PK/PD QTc modelling with the distinction of model types Reducing QTc variability in small studies

5 Data Quality in Small QTc Studies Electrocardiographic challenges of small clinical studies such as the first-in-man investigations Metrics of QTc data quality, power considerations of small studies Replacement and/or avoidance of standard positive control in small QTc studies and in conc-qtc analyses Approaches to PK/PD QTc modelling with the distinction of model types Reducing QTc variability in small studies

6 Data quality Small clinical studies

7 Small clinical studies Automatic ECG measurement

8 Error of an automatic measurement by a modern machine [ms] Average error [ms] (mean +SD) Treatment bias in automatic measurement QTcF in a quionolone study courtesy of Dr Sarapa 14 Placebo Treatment A 12 Treatment B P = 4 x P = 2 x Placebo Trearment A Treatment B Global median manual QT measurement [ms]

9 QT interval Small clinical studies Drug-induced heart rate changes Predose Tmax RR interval

10 QT interval QT interval QT interval Small clinical studies Drug-induced heart rate changes RR interval RR interval RR interval

11 QT interval QT interval QT interval Small clinical studies Drug-induced heart rate changes RR interval RR interval RR interval

12 QT interval [ms] QT interval [ms] QT interval [ms] QT interval [ms] Small clinical studies Baseline 1 Baseline Baseline 3 Baseline RR interval [ms] 320 Baseline 1 Baseline Baseline 3 Baseline RR interval [ms] Baseline 1 Baseline Baseline 3 Baseline RR interval [ms] 320 Baseline 1 Baseline Baseline 3 Baseline RR interval [ms]

13 Data Quality in Small QTc Studies Electrocardiographic challenges of small clinical studies such as the first-in-man investigations Metrics of QTc data quality, power considerations of small studies Replacement and/or avoidance of standard positive control in small QTc studies and in conc-qtc analyses Approaches to PK/PD QTc modelling with the distinction of model types Reducing QTc variability in small studies

14 Required number of subjects in a X-over study Standard deviation of QTc difference between placebo and period baseline [ms] Power of small TQT studies Comparisons 24 comparisons 40 comparisons s = 5.5 ms Time of the day [h] Expected QTc difference between Rx and placebo [ms]

15 Precision in QTc studies Metrics for comparison of data quality Intra-subject standard deviation of QTc on placebo

16 Data Quality in Small QTc Studies Electrocardiographic challenges of small clinical studies such as the first-in-man investigations Metrics of QTc data quality, power considerations of small studies Replacement and/or avoidance of standard positive control in small QTc studies and in conc-qtc analyses Approaches to PK/PD QTc modelling with the distinction of model types Reducing QTc variability in small studies

17 Assay sensitivity in QTc studies Electrocalrdiogram??? II Electrocardiogram??? V2 correlation coefficient of descending T waves difference 106 ms

18 Assay sensitivity in QTc studies Shift

19 Assay sensitivity in QTc studies

20 Assay sensitivity in QTc studies Reproducibility between subjects on placebo: Distribution of values (A t1 B t1 ) (A t2 B t2 ) where X t is QTc measured in placebo subject X at time t, for all pairs of placebo subjects A and B (A B) and all pairs of time-points t1 and t2 (t1 t2).

21 Data Quality in Small QTc Studies Electrocardiographic challenges of small clinical studies such as the first-in-man investigations Metrics of QTc data quality, power considerations of small studies Replacement and/or avoidance of standard positive control in small QTc studies and in conc-qtc analyses Approaches to PK/PD QTc modelling with the distinction of model types Reducing QTc variability in small studies

22 PK/PD models

23 PK/PD models

24 PK/PD models Linear Sigmoid E max E max Logarithmic

25 Data Quality in Small QTc Studies Electrocardiographic challenges of small clinical studies such as the first-in-man investigations Metrics of QTc data quality, power considerations of small studies Replacement and/or avoidance of standard positive control in small QTc studies and in conc-qtc analyses Approaches to PK/PD QTc modelling with the distinction of model types Reducing QTc variability in small studies

26 Reduction of QTc variability Submitted for publication on 6 th February 2015

27 APD/HR hysteresis Franz MR at al, J Clin Invest 1988; 82:

28 I QT/RR hysteresis II I II III avr avl avf V1 V2 V3 V4 V5 V6 III avr avl avf V1 V2 V3 V4 V5 V6

29 QT/RR hysteresis interval based interval based time based

30 Contribution of individual RR intervals QT/RR hysteresis 3.0% 2.5% 2.0% 1.5% 1.0% 0.5% 0.0% History of QT reading [cardiac cycles]

31 QT/RR hysteresis

32 QT/RR hysteresis

33 QT/RR hysteresis

34 QT/RR hysteresis

35 Correlation coefficient RR vs QTc=QT/RRa Correlation coefficient RR vs QTc=QT/RRa QT/RR hysteresis Correction coefficient a Correction coefficient a Fridericia correction

36 QT/RR hysteresis

37 QT/RR hysteresis

38 QT/RR hysteresis

39 QT/RR hysteresis It is pointless to try to stabilize HR by supine positions Correcting the QT intervals to the hysteresis modeled RR leads to substantial reduction of the QTc variability Correcting QT interval for simultaneously measured RR interval or an average of small number of RR intervals should be avoided Study analysis windows may include variable HR episodes

40 QT/RR hysteresis Preservation of the time course for hysteresis could serve the role of the positive control in TQTS, i.e., verification that the QT and RR data are adequate to detect clinically relevant repolarization effects of drugs where they exist.

41 Thank You

QT Studies for Biologics QT assessment in phase I Workshop 2

QT Studies for Biologics QT assessment in phase I Workshop 2 QT Studies for Biologics QT assessment in phase I Workshop 2 Philippe L Hostis Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH Berlin, 31st March 2011 QT assessment

More information

Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies. Corina Dota, AstraZeneca

Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies. Corina Dota, AstraZeneca Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies Corina Dota, AstraZeneca CSRC-2 th February 2012 ICH E14 2.2.5 Alternative Strategies to Assess QT/QTc Interval Effects Alternatives

More information

Implications of methodological differences in digital electrocardiogram interval measurement B

Implications of methodological differences in digital electrocardiogram interval measurement B Journal of Electrocardiology 39 (2006) S152 S156 www.elsevier.com/locate/jelectrocard Implications of methodological differences in digital electrocardiogram interval measurement B Fabio Badilini, PhD,

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

The Maximum Mean Difference

The Maximum Mean Difference The Maximum Mean Difference Statistical Problems in Assessing Cardiac Safety Georg Ferber, Novartis Pharma AG, Basel ROeS Seminar Bern, 10-13 Sep 2007 Overview QT prolongation some background The Thorough

More information

Pacing in Drug Testing

Pacing in Drug Testing ISHNE International Society for Holter and Noninvasive Electrocardiology 1 st Worldwide Internet Symposium on Drug- Induced QT Prolongation October 1-15, 1 15, 2007 Pacing in Drug Testing I Savelieva,

More information

Joint Annual meeting 2005 AGAH-Club Phase I

Joint Annual meeting 2005 AGAH-Club Phase I Joint Annual meeting 2005 AGAH-Club Phase I Early Drug Development Scientific and Regulatory challenges Strasbourg, March 17-18, 2005 Early drug development Scientific and Regulatory challenges QTc: Predictability,

More information

Design and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience

Design and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience Design and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience Dr. Manfred Wargenau, Institute, Düsseldorf OVERVIEW Clinical background The ICH E14 guideline / review

More information

IQ-CSRC PROSPECTIVE QTc STUDY Study Design and Choice of Drugs

IQ-CSRC PROSPECTIVE QTc STUDY Study Design and Choice of Drugs IQ-CSRC PROSPECTIVE QTc STUDY Study Design and Choice of Drugs Nenad Sarapa, MD IQ-CSRC meeting, Silver Spring, MD 12 December 2014 Background SAD studies can reliably assess QTc prolongation if proper

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Recent Developments in the Analysis of QT Interval Data

Recent Developments in the Analysis of QT Interval Data Recent Developments in the Analysis of QT Interval Data Robb Muirhead Statistical Research & Consulting Center Pfizer Global Statistics Graybill Conference VII Colorado State University June 12, 2008 1

More information

Guidance for Industry

Guidance for Industry Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department

More information

Definitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team

Definitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team Definitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team Jiang Liu, Ph.D. Scientific Lead for QT-IRT Division of Pharmacometrics Office of Clinical Pharmacology

More information

QT QT Study Design and Statistical Evaluation of QT Prolongation Introduction and QT Interval Correction

QT QT Study Design and Statistical Evaluation of QT Prolongation Introduction and QT Interval Correction QT QT Study Design and Statistical Evaluation of QT Prolongation Introduction and QT Interval Correction Yasushi Orihashi Clinical Data and Biostatistics Department, Daiichi Sankyo Co., Ltd. email: orihashi.yasushi.c2@daiichisankyo.co.jp

More information

Is there an "Adequate" Heart Rate Correction for QT?

Is there an Adequate Heart Rate Correction for QT? Is there an "Adequate" Heart Rate Correction for QT? R&D Information Technology, GGOIB Biometry&Biosignals Abbott GmbH&Co.KG D-67061 Ludwigshafen/Rhein International Biometric Society, German Region QT/QTc

More information

Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes

Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes Journal of Pharmacokinetics and Pharmacodynamics (2018) 45:491 503 https://doi.org/10.1007/s10928-018-9587-8 (0456789().,-volV)(0456789().,-volV) ORIGINAL PAPER Importance of QT/RR correction in studies

More information

IQ-CSRC PROSPECTIVE STUDY RESULTS. Steve Riley, PharmD, PhD IQ-CSRC meeting December 12, 2014

IQ-CSRC PROSPECTIVE STUDY RESULTS. Steve Riley, PharmD, PhD IQ-CSRC meeting December 12, 2014 IQ-CSRC PROSPECTIVE STUDY RESULTS Steve Riley, PharmD, PhD IQ-CSRC meeting December 12, 2014 IQ-CSRC prospective study - Design 20 male and female healthy subjects 3 treatment periods 9 subjects were to

More information

The QT Interval Safety Endpoint for DR- TB trials. Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology)

The QT Interval Safety Endpoint for DR- TB trials. Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology) The QT Interval Safety Endpoint for DR- TB trials Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology) The ECG tracing Physiology of a cardiac myocyte Flow of ions (Na

More information

ICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic

ICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic 25 January 2016 EMA/CHMP/ICH/310133/2008 Committee for Human Medicinal Products ICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic

More information

ICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS.

ICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS. European Medicines Agency London, 25 May 2005 CHMP/ICH/2/04 ICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS ICH Step 4 NOTE FOR

More information

Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes

Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes Based on Data from the Telemetric and Holter ECG Warehouse (THEW) Initiative Jean-PhiIippe Couderc, PhD Center for Quantitative

More information

FDA's Analysis and Interpretation of the IQ/CSRC Clinical Study

FDA's Analysis and Interpretation of the IQ/CSRC Clinical Study FDA's Analysis and Interpretation of the IQ/CSRC Clinical Study Jiang Liu Scientific Lead of QT-IRT Division of Pharmacometrics OCP/OTS/CDER/FDA Disclaimer: My remarks today do not necessarily reflect

More information

IQ/CSRC Study Waveform Sharing Program

IQ/CSRC Study Waveform Sharing Program IQ/CSRC Study Waveform Sharing Program Presentation for CSRC members August 26, 2015 Borje Darpo, icardiac Cindy Green, DCRI Georg Ferber, Independent Brian Smith, icardiac Jean-Philippe Couderc, THEW

More information

Preparing for Changing Cardiac Safety Regulations. Joy Olbertz, PharmD, PhD

Preparing for Changing Cardiac Safety Regulations. Joy Olbertz, PharmD, PhD Preparing for Changing Cardiac Safety Regulations Joy Olbertz, PharmD, PhD Questions? Do I still have to assess proarrhythmic potential of my compound in a Thorough QT (TQT) study? If I have a TQT to conduct,

More information

Food can serve as a non pharmacological control in thorough cardiac safety studies

Food can serve as a non pharmacological control in thorough cardiac safety studies Food can serve as a non pharmacological control in thorough cardiac safety studies Jorg Taubel MD FFPM Washington 14 th April 2011 Disclaimer The views and opinions expressed in the following PowerPoint

More information

Interpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety?

Interpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety? Interpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety? Hao Zhu, Ph.D. Scientific Lead, QT-IRT, FDA (Dec 10, 2010) Disclaimer: The views expressed in this talk are those of

More information

Concentration QTc Assessment in Early Phase Trials

Concentration QTc Assessment in Early Phase Trials Concentration QTc Assessment in Early Phase Trials Fang Liu*, Li Fan, Kuenhi Tsai, Devan V. Mehrotra ASA Biopharmaceutical Section Regulatory Industry Statistics Workshop September 14, 2018 Washington,

More information

Study Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg;

Study Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg; The study listed may include approved non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Implications of Individual QT/RR Profiles Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes

Implications of Individual QT/RR Profiles Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes Drug Safety https://doi.org/10.1007/s40264-018-0735-2 ORIGINAL RESEARCH ARTICLE Implications of Individual QT/RR Profiles Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies

More information

Breakout #4 Phase 1 ECG:

Breakout #4 Phase 1 ECG: Breakout #4 Phase 1 ECG: Potential Role of ECG under CiPA HESI CSRC CiPA Meeting Washington, DC - May 22, 2018 Jose Vicente, PhD Christine Garnett, PharmD Division of Cardiovascular and Renal Products

More information

For Discussion Purposes Only

For Discussion Purposes Only 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 Step 1 Draft 2 (July 17, 2003) Draft 3 (November 12, 2003), Draft 4 (June 10, 2004)

More information

QT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services

QT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services QT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services The Evolution of ICH E14 Points to Consider Joint Health Canada/FDA Concept Paper

More information

Implications of Individual QT/RR Profiles Part 1: Inaccuracies and Problems of Population Specific QT/Heart Rate Corrections

Implications of Individual QT/RR Profiles Part 1: Inaccuracies and Problems of Population Specific QT/Heart Rate Corrections Drug Safety https://doi.org/10.1007/s40264-018-0736-1 ORIGINAL RESEARCH ARTICLE Implications of Individual QT/RR Profiles Part 1: Inaccuracies and Problems of Population Specific QT/Heart Rate Corrections

More information

Guidance for Industry

Guidance for Industry Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs U.S. Department of Health and Human Services Food and Drug Administration

More information

TQT studies - this is the end!

TQT studies - this is the end! TQT studies - this is the end! Borje Darpo MD, PhD Associate Professor of Cardiology Chief Scientific Officer icardiac Technologies Yes as the only way to confidently exclude that a new drug has a clinically

More information

Comparison of Electrocardiographic Biomarkers for Differentiating. Drug-induced Single vs. Multiple Cardiac Ion Channel Block

Comparison of Electrocardiographic Biomarkers for Differentiating. Drug-induced Single vs. Multiple Cardiac Ion Channel Block Article Type: Article Comparison of Electrocardiographic Biomarkers for Differentiating Drug-induced Single vs. Multiple Cardiac Ion Channel Block Marina Brockway 1, Jay W. Mason 2,3, Brian P. Brockway

More information

Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity

Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity Drug Development Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity The Journal of Clinical Pharmacology 2018, 58(1) 81 88 C 2017, The Authors. The Journal of Clinical Pharmacology

More information

EXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS

EXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS EXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS Christine Garnett, PharmD DCRP, FDA April 6, 2016 CSRC/FDA Workshop: The Proarrhythmic Assessment of New Chemical Entities Disclosures

More information

ECG INTERPRETATION MANUAL

ECG INTERPRETATION MANUAL Lancashire & South Cumbria Cardiac Network ECG INTERPRETATION MANUAL THE NORMAL ECG Lancashire And South Cumbria Cardiac Physiologist Training Manual THE NORMAL ECG E.C.G CHECKLIST 1) Name, Paper Speed,

More information

5- The normal electrocardiogram (ECG)

5- The normal electrocardiogram (ECG) 5- The (ECG) Introduction Electrocardiography is a process of recording electrical activities of heart muscle at skin surface. The electrical current spreads into the tissues surrounding the heart, a small

More information

beyond AMPS LLC, New York, USA Hopital Lariboisiere, Paris, France

beyond AMPS LLC, New York, USA Hopital Lariboisiere, Paris, France The Holter bin approach and beyond Fabio Badilini, PhD AMPS LLC, New York, USA Pierre Maison-Blanche, MD Hopital Lariboisiere, Paris, France 1 Outlines Background of quantitative digital ECG The rate RR

More information

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,

More information

Alex Dmitrienko (Eli Lilly and Company), Chair of Distance Training, Biopharmaceutical Section of ASA

Alex Dmitrienko (Eli Lilly and Company), Chair of Distance Training, Biopharmaceutical Section of ASA Spring 2008 series Introduction Alex Dmitrienko (Eli Lilly and Company), Chair of Distance Training, Biopharmaceutical Section of ASA Assessment of QTc prolongation in clinical drug development Alex Dmitrienko

More information

INTRODUCTION TO ECG. Dr. Tamara Alqudah

INTRODUCTION TO ECG. Dr. Tamara Alqudah INTRODUCTION TO ECG Dr. Tamara Alqudah Excitatory & conductive system of the heart + - The ECG The electrocardiogram, or ECG, is a simple & noninvasive diagnostic test which records the electrical

More information

Recent insights from the FDA QT-IRT on concentration-qtc analysis and requirements for TQT study ( waiver ) substitution

Recent insights from the FDA QT-IRT on concentration-qtc analysis and requirements for TQT study ( waiver ) substitution Recent insights from the FDA QT-IRT on concentration-qtc analysis and requirements for TQT study ( waiver ) substitution Dhananjay D. Marathe, Ph.D. QT-IRT Lead, Office of Clinical Pharmacology US FDA

More information

Concentration-QTc analysis to obviate the need for a dedicated QTc study in cancer patients: ixazomib, an oral proteasome inhibitor, as a case study

Concentration-QTc analysis to obviate the need for a dedicated QTc study in cancer patients: ixazomib, an oral proteasome inhibitor, as a case study Concentration-QTc analysis to obviate the need for a dedicated QTc study in cancer patients: ixazomib, an oral proteasome inhibitor, as a case study Neeraj Gupta, Ph.D. Outline Concentration-QTc analysis

More information

Ectopic Beats, Activity Effects and Heart Rate Turbulence

Ectopic Beats, Activity Effects and Heart Rate Turbulence HRV 2006 Ectopic Beats, Activity Effects and Heart Rate Turbulence Gari Clifford gari@mit.edu www.mit.edu/~gari/ Harvard-MIT Division of Health Sciences & Technology Outline Overview of Cardiovascular

More information

Family Medicine for English language students of Medical University of Lodz ECG. Jakub Dorożyński

Family Medicine for English language students of Medical University of Lodz ECG. Jakub Dorożyński Family Medicine for English language students of Medical University of Lodz ECG Jakub Dorożyński Parts of an ECG The standard ECG has 12 leads: six of them are considered limb leads because they are placed

More information

Determining Axis and Axis Deviation on an ECG

Determining Axis and Axis Deviation on an ECG Marquette University e-publications@marquette Physician Assistant Studies Faculty Research and Publications Health Sciences, College of 7-15-2010 Determining Axis and Axis Deviation on an ECG Patrick Loftis

More information

The pharmacological positive control can be replaced by a meal.

The pharmacological positive control can be replaced by a meal. The pharmacological positive control can be replaced by a meal. Wednesday, April 6th, 2016 CSRC/FDA Workshop: The Pro-arrhythmic Assessment of New Chemical Entities ACC Heart House Washington, D.C. Jorg

More information

Drug Discoveries & Therapeutics. 2010; 4(1):44-53.

Drug Discoveries & Therapeutics. 2010; 4(1):44-53. 44 Drug Discoveries & Therapeutics. 21; 4(1):44-3. Original Article Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers Kevin R.

More information

Case-Based Practical ECG Interpretation for the Generalist

Case-Based Practical ECG Interpretation for the Generalist Case-Based Practical ECG Interpretation for the Generalist Paul D. Varosy, MD, FACC, FAHA, FHRS Director of Cardiac Electrophysiology VA Eastern Colorado Health Care System Associate Professor of Medicine

More information

EMA EFPIA workshop Breakout Session 2 Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Early Clinical Drug Development

EMA EFPIA workshop Breakout Session 2 Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Early Clinical Drug Development EMA EFPIA workshop Breakout Session 2 Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Early Clinical Drug Development Oscar Della Pasqua GSK Background Drugs that prolong QT

More information

Evaluation of the Effect of Dapagliflozin on Cardiac Repolarization: a Thorough QT/QTc Study

Evaluation of the Effect of Dapagliflozin on Cardiac Repolarization: a Thorough QT/QTc Study Diabetes Ther (2011) 2(3):123-132. DOI 10.1007/s13300-011-0003-2 ORIGINAL RESEARCH Evaluation of the Effect of Dapagliflozin on Cardiac Repolarization: a Thorough QT/QTc Study Glenn F. Carlson Conrad K.

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Lack of correlation between exercise and sibenadetinduced changes in heart rate corrected measurement of the QT interval

Lack of correlation between exercise and sibenadetinduced changes in heart rate corrected measurement of the QT interval et al. DOI:10.1111/j.1365-2125.2006.02763.x British Journal of Clinical Pharmacology Lack of correlation between exercise and sibenadetinduced changes in heart rate corrected measurement of the QT interval

More information

Study methodology for screening candidates to athletes risk

Study methodology for screening candidates to athletes risk 1. Periodical Evaluations: each 2 years. Study methodology for screening candidates to athletes risk 2. Personal history: Personal history of murmur in childhood; dizziness, syncope, palpitations, intolerance

More information

Bundle Branch & Fascicular Blocks. Reading Assignment (p53-58 in Outline )

Bundle Branch & Fascicular Blocks. Reading Assignment (p53-58 in Outline ) Bundle Branch & Fascicular Blocks Reading Assignment (p53-58 in Outline ) Objectives 1. QRS analysis of Right and Left BBB 2. Uncomplicated vs complicated BBB 3. Diagnosis of RBBB with LAFB and LPFB 4.

More information

The QT interval as it relates to the safety of non-cardiac drugs

The QT interval as it relates to the safety of non-cardiac drugs European Heart Journal Supplements (2007) 9 (Supplement G), G3 G8 doi:10.1093/eurheartj/sum047 The QT interval as it relates to the safety of non-cardiac drugs Peter R. Kowey 1 * and Marek Malik 2,3 1

More information

FANS Long QT Syndrome Investigation Protocol (including suspected mutation carriers)

FANS Long QT Syndrome Investigation Protocol (including suspected mutation carriers) Clinical Features FANS Long QT Syndrome Investigation Protocol (including suspected mutation carriers) History Syncope or presyncope compatible with ventricular tachyarrhythmia, especially relating to

More information

Pakistan Veterinary Journal

Pakistan Veterinary Journal RESEARCH ARTICLE Pakistan Veterinary Journal ISSN: 0253-8318 (PRINT), 2074-7764 (ONLINE) DOI: 10.29261/pakvetj/2018.115 Determination of Corrected QT Interval in Kangal Breed Dogs R Gonul, L Koenhemsı

More information

QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy

QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy European Heart Journal (1996) 17, 258-263 QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy L. Fei, J. H. Goldman,

More information

MARS Ambulatory ECG Analysis The power to assess and predict

MARS Ambulatory ECG Analysis The power to assess and predict GE Healthcare MARS Ambulatory ECG Analysis The power to assess and predict Connecting hearts and minds Prevention starts with knowledge Around the world, heart disease is one of our fastest-growing health

More information

Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC

Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride

More information

Chapter 2 Practical Approach

Chapter 2 Practical Approach Chapter 2 Practical Approach There are beginners in electrocardiogram (ECG) analysis who are fascinated by a special pattern (e.g., a bundle-branch block or a striking Q wave) and thereby overlook other

More information

QT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency

QT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency QT prolongation and drug-drug interactions Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency Disposition Introduction to QT prolongation Three relevant DDI scenarios Concluding

More information

Intravenous Conivaptan: Effects on the QTc Interval and Other Electrocardiographic Parameters in Healthy Volunteers

Intravenous Conivaptan: Effects on the QTc Interval and Other Electrocardiographic Parameters in Healthy Volunteers Advances in Therapy Volume 24 No. 2 March/April 2007 Intravenous Conivaptan: Effects on the QTc Interval and Other Electrocardiographic Parameters in Healthy Volunteers Kenneth C. Lasseter, MD Stacy C.

More information

Evaluation of Differences in Automated QT/QTc Measurements between Fukuda Denshi and Nihon Koden Systems

Evaluation of Differences in Automated QT/QTc Measurements between Fukuda Denshi and Nihon Koden Systems Evaluation of Differences in Automated QT/QTc Measurements between Fukuda Denshi and Nihon Koden Systems Motoaki Sano 1 *, Yoshiyasu Aizawa 1, Yoshinori Katsumata 1, Nobuhiro Nishiyama 1, Seiji Takatsuki

More information

ECG. Prepared by: Dr.Fatima Daoud Reference: Guyton and Hall Textbook of Medical Physiology,12 th edition Chapters: 11,12,13

ECG. Prepared by: Dr.Fatima Daoud Reference: Guyton and Hall Textbook of Medical Physiology,12 th edition Chapters: 11,12,13 ECG Prepared by: Dr.Fatima Daoud Reference: Guyton and Hall Textbook of Medical Physiology,12 th edition Chapters: 11,12,13 The Concept When the cardiac impulse passes through the heart, electrical current

More information

at least 4 8 hours per week

at least 4 8 hours per week ECG IN ATHLETS An athlete is defined as an individual who engages in regular exercise or training for sport or general fitness, typically with a premium on performance, and often engaged in individual

More information

short-term safety and tolerability of coadministration of ETR or DRV/rtv and artemether/lumefantrine in healthy subjects.

short-term safety and tolerability of coadministration of ETR or DRV/rtv and artemether/lumefantrine in healthy subjects. SYNOPSIS Issue Date: 6 March 2012 Name of Sponsor/Company Janssen EMEA Medical Affairs Name of Finished Product INTELENCE ; PREZISTA Name of Active Ingredient(s) etravirine (ETR, also known as TMC125);

More information

ELECTROCARDIOGRAPHY (ECG)

ELECTROCARDIOGRAPHY (ECG) ELECTROCARDIOGRAPHY (ECG) The heart is a muscular organ, which pumps blood through the blood vessels of the circulatory system. Blood provides the body with oxygen and nutrients, as well as assists in

More information

The ABC of Pediatric ECG

The ABC of Pediatric ECG The ABC of Pediatric ECG Mohamed Hamdan, MD, FAAP, FACC Assistant Professor of Pediatrics Columbia University College of Physicians and Surgeons, NY, USA Consultant Pediatric Cardiologist & Co-Director

More information

Is a Maximal Tolerated Dose in Human useful for drug development?

Is a Maximal Tolerated Dose in Human useful for drug development? Is a Maximal Tolerated Dose in Human useful for drug development? How to define an acceptable highest dose to be tested? EuFeMED, London Pre-conference Workshop 17-May-2017 Eric Legangneux Philippe Grosjean

More information

This presentation will deal with the basics of ECG description as well as the physiological basics of

This presentation will deal with the basics of ECG description as well as the physiological basics of Snímka 1 Electrocardiography basics This presentation will deal with the basics of ECG description as well as the physiological basics of Snímka 2 Lecture overview 1. Cardiac conduction system functional

More information

New ECG Biomarkers and their Potential Role in CiPA: Results and Implications

New ECG Biomarkers and their Potential Role in CiPA: Results and Implications New ECG Biomarkers and their Potential Role in CiPA: Results and Implications HESI CSRC CiPA Meeting Washington, DC - May 21, 2018 Jose Vicente, PhD for the ECG Biomarker Working Group Division of Cardiovascular

More information

A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology

A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology Martino Vaglio, MS, Jean-Philippe Couderc, PhD, MBA, Scott McNitt, MS, Xiaojuan

More information

ECG-PS ECG SIGNAL MEASUREMENT MODULE. Operation Manual. March 2005

ECG-PS ECG SIGNAL MEASUREMENT MODULE. Operation Manual. March 2005 ECG-PS ECG SIGNAL MEASUREMENT MODULE Operation Manual March 2005 2555 Collins Avenue, Suite C-5 - Miami Beach FL - 33140 - U.S.A. Phone #: (305) 534-5905 Fax: (305) 534-8222 e-mail: info@galix-gbi.com

More information

DR QAZI IMTIAZ RASOOL OBJECTIVES

DR QAZI IMTIAZ RASOOL OBJECTIVES PRACTICAL ELECTROCARDIOGRAPHY DR QAZI IMTIAZ RASOOL OBJECTIVES Recording of electrical events in heart Established electrode pattern results in specific tracing pattern Health of heart i. e. Anatomical

More information

ELECTROCARDIOGRAPH. General. Heart Rate. Starship Children s Health Clinical Guideline

ELECTROCARDIOGRAPH. General. Heart Rate. Starship Children s Health Clinical Guideline General Heart Rate QRS Axis T Wave Axis PR Interval according to Heart Rate & Age P Wave Duration and Amplitude QRS Duration according to Age QT Interval R & S voltages according to Lead & Age R/S ratio

More information

Understanding basics of EKG

Understanding basics of EKG Understanding basics of EKG By Alula A.(R III) www.le.ac.uk Topic for discussion Understanding of cellular electrophysiology Basics Rate Rhythm Axis Intervals P wave QRS ST/T wave Abnormal EKGs Understanding

More information

available at journal homepage:

available at   journal homepage: Journal of Cardiology (2011) 57, 269 274 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jjcc Original article QT/RR relation during atrial fibrillation based on a single beat

More information

Electrocardiography Abnormalities (Arrhythmias) 7. Faisal I. Mohammed, MD, PhD

Electrocardiography Abnormalities (Arrhythmias) 7. Faisal I. Mohammed, MD, PhD Electrocardiography Abnormalities (Arrhythmias) 7 Faisal I. Mohammed, MD, PhD 1 Causes of Cardiac Arrythmias Abnormal rhythmicity of the pacemaker Shift of pacemaker from sinus node Blocks at different

More information

Electrocardiogram ECG. Hilal Al Saffar FRCP FACC College of medicine,baghdad University

Electrocardiogram ECG. Hilal Al Saffar FRCP FACC College of medicine,baghdad University Electrocardiogram ECG Hilal Al Saffar FRCP FACC College of medicine,baghdad University Tuesday 29 October 2013 ECG introduction Wednesday 30 October 2013 Abnormal ECG ( ischemia, chamber hypertrophy, heart

More information

Identification of Ischemic Lesions Based on Difference Integral Maps, Comparison of Several ECG Intervals

Identification of Ischemic Lesions Based on Difference Integral Maps, Comparison of Several ECG Intervals 1.2478/v148-9-21-7 MEASUREMENT SCIENCE REVIEW, Volume 9, No. 5, 29 Identification of Ischemic Lesions Based on Difference Integral Maps, Comparison of Several ECG Intervals J. Švehlíková, M. Kania 1, M.

More information

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers). Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,

More information

Characteristics of the atrial repolarization phase of the ECG in paroxysmal atrial fibrillation patients and controls

Characteristics of the atrial repolarization phase of the ECG in paroxysmal atrial fibrillation patients and controls 672 Acta Cardiol 2015; 70(6): 672-677 doi: 10.2143/AC.70.6.3120179 [ Original article ] Characteristics of the atrial repolarization phase of the ECG in paroxysmal atrial fibrillation patients and controls

More information

CSRC White Papers. An update Dec. 2010

CSRC White Papers. An update Dec. 2010 CSRC White Papers An update Dec. 2010 Ignacio Rodriguez, MD Clinical Safety Risk Management Roche ignacio.rodriguez.ir1@roche.com CSRC White Papers Position papers usually cover challenging areas of cardiovascular

More information

10 ECGs No Practitioner Can Afford to Miss. Objectives

10 ECGs No Practitioner Can Afford to Miss. Objectives 10 ECGs No Practitioner Can Afford to Miss Mary L. Dohrmann, MD Professor of Clinical Medicine Division of Cardiovascular Medicine University of Missouri School of Medicine No disclosures Objectives 1.

More information

Introduction to ECG Gary Martin, M.D.

Introduction to ECG Gary Martin, M.D. Brief review of basic concepts Introduction to ECG Gary Martin, M.D. The electrical activity of the heart is caused by a sequence of rapid ionic movements across cell membranes resulting first in depolarization

More information

Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model

Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model Citation: CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 1 9; doi:10.1002/psp4.14 VC 2015 ASCPT All rights reserved ORIGINAL ARTICLE Evaluating the Use of Linear Mixed-Effect Models for Inference of the

More information

Research Article QT Measurement and Heart Rate Correction during Hypoglycemia: Is There a Bias?

Research Article QT Measurement and Heart Rate Correction during Hypoglycemia: Is There a Bias? SAGE-Hindawi Access to Research Cardiology Research and Practice Volume 2010, Article ID 961290, 6 pages doi:10.4061/2010/961290 Research Article QT Measurement and Heart Rate Correction during Hypoglycemia:

More information

Speed - Accuracy - Exploration. Pathfinder SL

Speed - Accuracy - Exploration. Pathfinder SL Speed - Accuracy - Exploration Pathfinder SL 98000 Speed. Accuracy. Exploration. Pathfinder SL represents the evolution of over 40 years of technology, design, algorithm development and experience in the

More information

Comparison of Two Highly Automated ECG Algorithms for Detection of Drug-Induced Cardiac Ion Channel Block

Comparison of Two Highly Automated ECG Algorithms for Detection of Drug-Induced Cardiac Ion Channel Block Comparison of Two Highly Automated ECG Algorithms for Detection of Drug-Induced Cardiac Ion Channel Block Marina Brockway 1, Anthony A. Fossa 2 and Jay W. Mason 3,4 US Food and Drug Administration (FDA)

More information

BASIC CONCEPT OF ECG

BASIC CONCEPT OF ECG BASIC CONCEPT OF ECG Electrocardiogram The electrocardiogram (ECG) is a recording of cardiac electrical activity. The electrical activity is readily detected by electrodes attached to the skin. After the

More information

General Introduction to ECG. Reading Assignment (p2-16 in PDF Outline )

General Introduction to ECG. Reading Assignment (p2-16 in PDF Outline ) General Introduction to ECG Reading Assignment (p2-16 in PDF Outline ) Objectives 1. Practice the 5-step Method 2. Differential Diagnosis: R & L axis deviation 3. Differential Diagnosis: Poor R-wave progression

More information

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page: SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With

More information

Myocardial Infarction. Reading Assignment (p66-78 in Outline )

Myocardial Infarction. Reading Assignment (p66-78 in Outline ) Myocardial Infarction Reading Assignment (p66-78 in Outline ) Objectives 1. Why do ST segments go up or down in ischemia? 2. STEMI locations and culprit vessels 3. Why 15-lead ECGs? 4. What s up with avr?

More information

Preface: Wang s Viewpoints

Preface: Wang s Viewpoints AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part IV, Ischemia and Infarction Presented by: WANG, TZONG LUEN, MD, PhD, JM, FACC, FESC, FCAPSC Professor,

More information